High Growth Tech Stocks in Canada for September 2024

The Canadian market has experienced increased volatility recently, driven by concerns over a slowing economy and persistent inflation, yet stocks have managed to deliver strong gains and remain near record highs. In this environment, identifying high-growth tech stocks becomes crucial as they often possess the innovation and resilience needed to thrive amid economic fluctuations.

Top 10 High Growth Tech Companies In Canada

Name	Revenue Growth	Earnings Growth	Growth Rating
Docebo	14.71%	33.96%	★★★★★☆
Constellation Software	16.17%	23.55%	★★★★★☆
HIVE Digital Technologies	54.20%	100.27%	★★★★★☆
GameSquare Holdings	38.08%	86.64%	★★★★★☆
Blackline Safety	22.54%	162.50%	★★★★★☆
Medicenna Therapeutics	62.37%	57.20%	★★★★★☆
Cineplex	7.33%	179.27%	★★★★☆☆
Sabio Holdings	12.97%	122.50%	★★★★☆☆
BlackBerry	20.61%	76.74%	★★★★★☆
Alpha Cognition	62.98%	69.54%	★★★★★☆

Click here to see the full list of 24 stocks from our TSX High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

Constellation Software (TSX:CSU)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Constellation Software Inc., along with its subsidiaries, acquires, builds, and manages vertical market software businesses in Canada, the United States, Europe, and internationally with a market cap of CA$92.30 billion.

Operations: Constellation Software Inc. generates revenue primarily from its Software & Programming segment, amounting to $9.27 billion. The company focuses on acquiring and managing vertical market software businesses across various regions including Canada, the United States, and Europe.

Constellation Software's revenue growth of 16.2% annually, though slower than some peers, is still robust compared to the Canadian market's 6.9%. Earnings are projected to rise by 23.6% per year, significantly outpacing the broader market's 15.2%. The recent launch of Omegro consolidates over 30 business units and serves more than 15,000 customers globally, enhancing its software offerings across diverse sectors like ERP and logistics management. R&D expenses have consistently supported innovation within these segments.

• Click here and access our complete health analysis report to understand the dynamics of Constellation Software.

• Gain insights into Constellation Software's past trends and performance with our Past report.

Docebo (TSX:DCBO)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Docebo Inc. operates as a learning management software company that provides an AI-powered learning platform in North America and internationally, with a market cap of CA$1.76 billion.

Operations: The company generates revenue primarily from its educational software segment, which reported $200.24 million in revenue. The AI-powered learning platform is the core product driving these sales across North America and international markets.

Docebo's revenue growth of 14.7% annually outpaces the Canadian market's 6.9%, with earnings projected to rise by 34% per year, significantly higher than the broader market's 15.2%. The company reported Q2 sales of $53.05 million, up from $43.59 million a year ago, and net income of $4.7 million compared to a net loss previously. R&D expenses support innovation in their SaaS model, ensuring recurring revenue streams from subscriptions and enhancing their competitive edge in e-learning solutions.

• Navigate through the intricacies of Docebo with our comprehensive health report here.

• Examine Docebo's past performance report to understand how it has performed in the past.

Vitalhub (TSX:VHI)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Vitalhub Corp., along with its subsidiaries, offers technology solutions for health and human service providers across Canada, the United States, the United Kingdom, Australia, Western Asia, and other international markets with a market cap of CA$446.49 million.

Operations: Vitalhub Corp. generates revenue primarily from its healthcare software segment, which amounted to CA$58.32 million. The company serves health and human service providers across multiple international markets including Canada, the United States, the United Kingdom, Australia, and Western Asia.

Vitalhub's revenue surged to CAD 16.24 million in Q2 2024, up from CAD 13.09 million the previous year, showcasing a robust growth trajectory of 13.5% annually, outpacing the Canadian market's 6.9%. Despite a net loss of CAD 0.34 million this quarter, its earnings are forecasted to grow by an impressive 65.9% per year over the next three years, significantly higher than the broader market’s projected growth rate of 15.2%. The company’s R&D expenditure supports advancements in healthcare software solutions, ensuring continued innovation and competitive positioning within its industry segment.

• Delve into the full analysis health report here for a deeper understanding of Vitalhub.

• Explore historical data to track Vitalhub's performance over time in our Past section.

Make It Happen

• Gain an insight into the universe of 24 TSX High Growth Tech and AI Stocks by clicking here.
• Are you invested in these stocks already? Keep abreast of every twist and turn by setting up a portfolio with Simply Wall St, where we make it simple for investors like you to stay informed and proactive.
• Invest smarter with the free Simply Wall St app providing detailed insights into every stock market around the globe.

Interested In Other Possibilities?

• Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
• Fuel your portfolio with companies showing strong growth potential, backed by optimistic outlooks both from analysts and management.
• Find companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com